Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Restem LLC is currently prosecuting 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners and are located within 2 distinct art units. BELYAVSKYI, MICHAIL A is the busiest examiner, holding 1 busiest examiner pending action.
The distribution of 2 pending office actions among 2 distinct examiners indicates that the workload is evenly split. Furthermore, the involvement of 2 distinct art units suggests that the 2 pending matters involve different technical sub-specialties. BELYAVSKYI, MICHAIL A is responsible for 1 busiest examiner pending action, which is exactly half of the company's active prosecution. For a practitioner, this means there is no examiner concentration to leverage across the portfolio. Each of the 2 pending office actions must be handled as an independent matter, as the 2 distinct examiners and 2 distinct art units provide no overlap for consolidating arguments or examiner interviews in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 2 | 42.2% | +24.7% |
| BELYAVSKYI, MICHAIL A | 1 | 64.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17390574 | FACTOR RICH PRODUCT FROM UMBILICAL CORD MESENCHYMAL STEM CELLS | CLARKE, TRENT R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17874767 | METHODS AND COMPOSITIONS OF NATURAL KILLER CELL ADOPTIVE TRANSFER THERAPY | BELYAVSKYI, MICHAIL A | — |
| 17390574 | FACTOR RICH PRODUCT FROM UMBILICAL CORD MESENCHYMAL STEM CELLS | CLARKE, TRENT R | — |
| 17205910 | COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | CLARKE, TRENT R | — |
| Art Unit | Apps |
|---|---|
| 1651 | 2 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17874767 | METHODS AND COMPOSITIONS OF NATURAL KILLER CELL ADOPTIVE TRANSFER THERAPY | BELYAVSKYI, MICHAIL A | 1644 | §102DP | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17390574 | FACTOR RICH PRODUCT FROM UMBILICAL CORD MESENCHYMAL STEM CELLS | CLARKE, TRENT R | 1651 | §103§112 | Final Rejection | — | Pending | Jul 30, 2021 |
| 17205910 | COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | CLARKE, TRENT R | 1651 | §103 | Final Rejection | — | Pending | Mar 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRestem LLC has 3 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Trent R Clarke has the most, with 2 of Restem LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.